"Exelixis Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU."
021421 Exelixis Highlights Positive Resu
Download • 216KB
Medical - Pharma - Biotech - Medical Devices - Healthcare - Telemedicine - Healthcare Technology - Healthcare IT
Your Source For Worldwide Business and Financial Opportunities
MedNews on financings, strategic relationships, products, services and technology, including launches
MedTalks videos featuring conversations with management of companies with business or financial objectives